Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNK3 | O14649 | 4/20 | 0.61 |
| ▸ | KCNK9 | Q9NPC2 | 3/20 | 0.61 |
| ▸ | NT5E | P21589 | 1/20 | 0.58 |
| ▸ | BRAF | P15056 | 10/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.50 |
| ▸ | DNMT3A | Q9Y6K1 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24011296 | 1.00 | KCNK3 (0.61) | KCNK3KCNK9NT5EBRAFKCNH2 | |
| SCHEMBL30290950 | 1.00 | KCNK3 (0.61) | KCNK3KCNK9NT5EBRAFKCNH2 | |
| SCHEMBL30290838 | 1.00 | KCNK3 (0.61) | KCNK3KCNK9NT5EBRAFKCNH2 | |
| SCHEMBL30287680 | 0.95 | NT5E (0.61) | KCNK3KCNK9NT5EBRAFLMNA | |
| SCHEMBL24006367 | 0.95 | NT5E (0.61) | KCNK3KCNK9NT5EBRAFLMNA | |
| SCHEMBL24010908 | 0.95 | BRAF (0.61) | KCNK3KCNK9NT5EBRAFKCNH2 | |
| SCHEMBL30290852 | 0.95 | BRAF (0.61) | KCNK3KCNK9NT5EBRAFKCNH2 | |
| SCHEMBL24010657 | 0.94 | BRAF (0.57) | KCNK3KCNK9BRAFKCNH2ALDH1A1 | |
| SCHEMBL30290919 | 0.94 | BRAF (0.57) | KCNK3KCNK9BRAFKCNH2ALDH1A1 | |
| SCHEMBL24004056 | 0.93 | KCNK3 (0.57) | KCNK3KCNK9NT5EBRAFHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219927-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-07-13 | — | — | US | disclosed |
| CN-115996721-A | AKT3 modulators | 乔治穆内有限责任公司 | 2023-04-21 | — | — | CN | disclosed |
| WO-2021226458-A1 | AKT3 MODULATORS | GEORGIAMUNE LLC (US) | 2021-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219927-A1 | AKT3 MODULATORS | AKT3, AKT2, PIK3CA | KCNK3 2240/4885KCNK9 4540/4885NT5E 4655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.